Recombinant Adenovirus Vector Design for Invading Immune System
The viral vector is a potent gene delivery platform for the treatment of genetic and acquired diseases. The removal of pathogenicity and replication of adenovirus, combined with its ability to carry the therapeutic transgene and to effectively infect numerous mammalian cells makes it amenable for clinical use in gene therapy. Especially, recombinant adenoviral vectors have been extensively used in gene transfer systems. As a leading expert in adenovirus manufacturing, Creative Biolabs offers custom adenovirus services ranging from vector design, small-scale packaging, to large-scale production for animal studies and clinical applications. Our professional team will work with global scientists to accomplish varieties of challenging adenovirus construction programs that best meet clients' needs.
Immune Responses to Viral Vectors
The adenoviral vector is an optimal vehicle for gene delivery due to its capacity to efficiently infect host cells, however, the immune system has evolved to fight off what it detects as invading pathogens. While innate immunity is mostly driven by virion components present on initial administration of the adenovirus into living animals, adaptive immune responses are primarily associated with the leaky expression of adenovirus-derived genes in the early generation of adenoviral vectors, or more importantly driven if the transgene expressed by adenoviral vectors is perceived as immunologically foreign. Thus, innate immunity and antigen-specific adaptive immune response against vector-derived immunogens reduce the stability and efficacy of in vivo gene transfer.
Figure 1. An overview of the innate response to Ad vectors.1
Recombinant Adenovirus Vector Design Services at Creative Biolabs
Immune responses against adenovirus may target capsid proteins, DNA or RNA genome, viral proteins expressed from vector backbone or incorporated genes, and strictly limit gene therapy in vivo. Systemic delivery of adenoviral vectors leads to rapid physiological reactions, including innate immunity activation, cytokine induction, inflammation, liver toxicity, and thrombocytopenia. Adenoviral vectors with additional deletions in their genome in the adenovirus genes (E2A, E2B, and E4) have been generated. These advanced vectors can produce fewer adenovirus-derived gene products and minimize the induction of vector-specific adaptive immunity.
I. Custom Vector Design & Engineering Phase
We start from scratch with your Gene of Interest (GOI) to ensure the genetic blueprint is optimized for minimal immune interference and maximum tissue specificity.
| Design Component | Technical Capability & Implementation | Research Advantage |
|---|---|---|
| GOI & Codon Optimization | De novo synthesis with mammalian codon bias adjustment and CpG island depletion. | Enhances translation efficiency while reducing TLR9-mediated innate recognition. |
| Promoter Engineering | Selection of tissue-specific (e.g., Synapsin, Albumin) or inducible (Rapamycin/Tet) promoters. | Prevents off-target expression in professional APCs, limiting adaptive immune priming. |
| Shuttle Architecture | Custom design of the ideal shuttle vector (pShuttle) for seamless recombination. | Ensures stable integration of complex multi-gene or shRNA expression cassettes. |
| miRNA-Detargeting | Integration of cell-type-specific miRNA target sequences (e.g., miR-142-3p) in the 3' UTR. | Actively suppresses transgene expression in hematopoietic lineages and dendritic cells. |
II. Capsid Shielding & Pseudotyping
To evade pre-existing neutralizing antibodies and innate immune sensors, we provide physical capsid modifications. This includes precise chemical PEGylation (polymer shielding), genetic incorporation of immune-modulating ligands. These modifications allow the vector to remain "invisible" to the humoral immune system during systemic circulation.
III. Scalable Viral Packaging & Amplification
Our wet-lab facilities are equipped to handle projects ranging from initial pilot studies to high-volume preclinical manufacturing.
| Production Scale | System Specifications | Target Applications |
|---|---|---|
| Vector Rescue | Efficient transfection into specialized HEK293 or E2/E4-complementing cell lines. | Generation of the primary seed stock for newly engineered or deleted backbones. |
| Small-Scale Packaging | Pilot-scale amplification with rigorous titer verification. | In vitro validation, screening assays, and initial proof-of-concept experiments. |
| Large-Scale Bioreactor | Multi-liter suspension culture production using high-yield producer lines. | Comprehensive in vivo studies, toxicology testing, and NHP (Non-Human Primate) trials. |
| Custom Amplification | Optimized protocols for "Gutless" or multiply deleted rAd. | Projects requiring ultra-high purity and massive genomic payload delivery. |
Features of Our Services
At Creative Biolabs, we're skilled at making newer adenoviral vectors eliciting lower immunogenicity and longer transgene expression, and our services can invade the immune system as below.
- Innate immune responses to adenoviral vectors
- Adaptive immune responses against adenoviral vectors
- Overcoming immune responses in adenoviral gene transfer
Recombinant adenovirus can infect a wide range of cell types with the highest efficiency and this infection isn't dependent on cell division of hosts. It has become a versatile and powerful tool for gene delivery and expression in mammalian cells. Here, we're able to produce custom recombinant adenovirus comprising full-length cDNA, allowing high gene expression, or an adenovirus construct containing RNAi oligos specific to a target gene to perform efficient elimination. In addition, we would also like to provide two kinds of vectors, the shuttle vector containing the gene of interest (GOI) and the recombinant adenovirus vector (pAD), for recombinant adenovirus packaging.
Our Immune-Evasion Engineering Strategies
We integrate multiple advanced engineering approaches to overcome immune barriers:
Multi-Deletion Adenoviral Backbones
- E1/E3 deletion (replication-deficient vectors)
- E2A, E2B, E4 deletions
- Helper-dependent adenovirus (HD-Ad, gutless vectors)
✔ Result: Reduced viral gene expression and lower adaptive immunity
Capsid Engineering & Shielding
- Hexon and fiber protein modification
- PEGylation or polymer coating
- Serotype switching or pseudotyping
✔ Result: Reduced neutralizing antibody recognition and improved circulation
Transgene Expression Optimization
- Tissue-specific promoters
- Inducible expression systems
- microRNA-regulated expression
✔ Result: Targeted expression with reduced off-target immune activation
Genome-Level Optimization
- CpG depletion
- Codon optimization
- Removal of immunogenic motifs
✔ Result: Reduced innate immune sensing
Complete Service Workflow
Creative Biolabs offers a true "one-stop-shop" wet-lab experience. Our modular workflow ensures strict quality control at every phase of the vector lifecycle.
-
Step 1: Consultation and Custom Vector Strategy
Our Ph.D.-level virologists will consult with you to understand your target tissue, duration requirements, and the immunological landscape of your animal model. We will propose a custom combination of the immune-evasion strategies detailed above.
-
Step 2: Shuttle Plasmid Design & De Novo Synthesis
We design and construct the necessary shuttle vectors. This includes optimizing the sequence of your Gene of Interest (GOI), selecting the appropriate promoters (ubiquitous, tissue-specific, or inducible), and incorporating any necessary microRNA target sequences or co-expression cassettes.
-
Step 3: Recombination & Rescue
Using advanced homologous recombination techniques in optimized bacterial strains or direct in vitro ligation, we generate the full-length recombinant adenoviral genome. We then transfect this massive DNA construct into highly specialized packaging cell lines to rescue the primary viral particles.
-
Step 4: Amplification & High-Titer Production
We scale up viral production in adherence to strict biological protocols. Whether you need small-scale production for in vitro screening or massive, large-scale bioreactor runs for non-human primate (NHP) studies, our facilities are equipped to handle the demand.
-
Step 5: Premium Purification (In Vivo Grade)
We utilize Double-Cesium Chloride (CsCl) Density Gradient Ultracentrifugation or advanced Ion-Exchange Chromatography. This removes empty capsids, defective interfering particles, and host cell proteins, yielding exceptionally pure, high-infectivity virions.
-
Step 6: Rigorous Quality Control (QC) Analytics
Every batch of virus is delivered with a comprehensive Certificate of Analysis (CoA) detailing:
- Physical Titer (Viral Particles - VP/mL): Determined by Optical Density (OD260) or quantitative PCR.
- Infectious Titer (Plaque Forming Units - PFU/mL or TCID50): Determining the actual infectivity ratio.
- Purity: SDS-PAGE and silver staining to ensure the absence of contaminating host proteins.
- Safety Testing: Strict testing for Replication Competent Adenovirus (RCA) limits, sterility, endotoxin levels, and mycoplasma, ensuring the vector itself does not cause artifactual immune activation in your models.
Applications in Modern Gene Therapy
Our immune-evading adenoviral vectors are currently empowering breakthrough research across multiple disciplines:
Systemic Gene Therapy
Treating monogenic disorders where long-term, systemic expression without immune clearance is mandatory.
Vaccine Development
Developing advanced viral vectored vaccines where the immune response is strictly directed toward the pathogen antigen, not the vector backbone, allowing for homologous prime-boost regimens.
Oncolytic Virotherapy
Designing "stealth" oncolytic adenoviruses capable of surviving systemic delivery (intravenous injection) to reach metastatic tumor sites before being cleared by neutralizing antibodies.
Chronic Disease Modeling
Establishing long-term animal models for chronic diseases using specific gene knockdown (shRNA/CRISPR) or overexpression without the confounding variables of vector-induced inflammation.
Why Choose Creative Biolabs?
When your research depends on navigating the complex host immune system, you need a partner with deep virological expertise and robust manufacturing capabilities.
- True Wet-Lab Capabilities: We deliver physical, high-titer, ready-to-inject viral preparations, not just computational models.
- Deep Immunological Insights: Our Ph.D.-level scientists design your vectors specifically anticipating innate and adaptive immune hurdles.
- Uncompromising Quality: Every batch is tested for RCA limits, endotoxin levels, and physical-to-infectious ratios.
- Complete Flexibility: From rare serotypes to 36kb vectors, we offer the most versatile adenoviral platform in the industry.
Frequently Asked Questions (FAQ)
Q: Why should I choose an immune-evading adenovirus vector over a standard first-generation (E1/E3 deleted) Ad5 vector?
A: Standard first-generation Ad5 vectors still possess "leaky" viral gene expression. In in vivo models, this leads to the presentation of viral antigens, triggering a rapid clearance of transduced cells by cytotoxic T lymphocytes (CTLs), usually within 2 to 4 weeks. Furthermore, their capsids can trigger strong innate inflammatory responses. Our immune-evading vectors (such as multiply deleted or Helper-Dependent vectors) are engineered to minimize or completely eliminate viral gene expression. This allows for long-term, stable transgene expression while significantly reducing hepatotoxicity and systemic inflammation in your animal models.
Q: What is the maximum gene payload capacity for your highly modified adenoviral vectors?
A: The payload capacity depends on the specific immune-evasion strategy selected. For our advanced Second-Generation (multiply deleted) vectors, we can typically accommodate inserts up to 8-10 kb. If your project involves massive multi-gene cassettes, large tissue-specific promoters, or complex CRISPR/Cas systems, we highly recommend our Helper-Dependent Adenoviral (HDAd) vectors, which provide an unparalleled cloning capacity of up to 36 kb while offering the lowest possible immunogenicity.
Q: My animal model (or target patient population) has pre-existing immunity to Ad5. How can your service help overcome this?
A: We offer two primary wet-lab strategies to bypass pre-existing neutralizing antibodies (NAbs). First, we provide Serotype Switching (Pseudotyping), constructing vectors using rare human serotypes (e.g., Ad35, Ad11) or non-human adenoviruses (e.g., chimpanzee Ad) that the host immune system has not encountered. Second, we can perform precise chemical PEGylation of the viral capsid. This polymer shielding physically masks the highly immunogenic hexon and fiber epitopes, allowing the vector to circulate undetected by pre-existing humoral immunity.
Partner with Creative Biolabs
Replication-deficient adenovirus-based recombinant vectors have been the focus of considerable interest in the current for their potential applications in gene therapy and as vaccine vehicles for treating infectious diseases. The innate immune response against adenoviruses is the most significant barrier in clinical practice of adenoviral vectors for gene therapy. At Creative Biolabs, we're always absorbed in exploring and investigating the mechanisms that adenoviral vectors interact with and activate the innate and adaptive immune systems. In this respect, our safer vectors allow for pre-emptive and specific modulation of immune responses in efforts to consider better utilization of these excellent gene transfer platforms. For more detailed information, please feel free to contact us or directly send us a quote.
Reference
- Wang Y, Shao W. Innate immune response to viral vectors in gene therapy. Viruses, 2023, 15(9): 1801. https://doi.org/10.3390/v15091801 Distributed under Open Access license CC BY 4.0, without modification.
